After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD

Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.

Human brain illustrated with millions of small nerves - Conceptual 3d render

Industry executives and biopharmaceutical analysts are reluctant to say that the failure of Eli Lilly & Co.’s solanezumab in a third Phase III clinical trial is the end of the road for the amyloid-beta hypothesis in Alzheimer’s disease, so does that mean another company could effectively treat the memory-stealing affliction with a drug that targets the menacing protein, or will other approaches be required?

The answer seems to be that multiple and combined approaches will be needed to slow the progression of Alzheimer’s and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category